Google told Adweek on 12 October 2026 that it is testing standard text and Shopping ads for certain pharmaceutical products inside AI Mode and AI Overviews, limited to the US. The ads are labelled "Sponsored", and advertisers reportedly need Google's pharmaceutical certification. It is a test, not a rollout, and most details beyond that come from secondary reports. This post covers what is confirmed as of 14 October 2026 and what a health marketer should do this week.
Key Takeaways
- Confirmed by a Google spokesperson to Adweek: a US test of text and Shopping ads, including certain pharma products, in AI Mode and AI Overviews, started in October 2026.
- Google told Search Engine Roundtable there were no recent policy changes, and Barry Schwartz said he could not find live examples.
- This follows a June 2026 healthcare test that excluded ads with pinning or text disclaimers.
- Eligibility does not equal delivery. Google Ads has no AI-placement report, so you need independent tracking.
- Everything here concerns the US test. I found nothing confirming an India or wider rollout.
- Organic AI visibility for medical topics still depends on YMYL-grade sourcing; ads do not replace it.
Verified as of 14 October 2026 from public reporting. This is marketing analysis, not legal or regulatory advice.
What is actually confirmed
Adweek's report, dated 12 October, quotes a Google spokesperson: "We're testing standard text and Shopping ads in AI Mode and AI Overviews," adding that these formats recently expanded to include certain pharmaceutical products. The article is paywalled, so I relied on the visible portion.
Search Engine Roundtable's 13 October post adds three details. Testing began in October, it is limited to the US, and Google said there were no recent policy changes. Barry Schwartz also said he tried to find such ads and did not see any, so treat reports of live placements as unconfirmed.
What is reported but harder to confirm
Shopifreaks summarises Adweek and adds that pharma certification is required, that AI will not rewrite the ads, and that disclaimers are allowed in some campaign types. EMARKETER likewise says experimental AI-rewritten formats are barred and that existing prescription rules apply. I could not see Google's own documentation of these points, so I label them "as reported".
How we got here: the June healthcare test
On 2 June 2026, Search Engine Land reported that Google Ads Liaison Ginny Marvin confirmed a small healthcare test in AI Mode. It was US-only, English-only, and open to Performance Max, AI Max with search term matching, Shopping and broad match. Only ads without pinned assets or text disclaimers were eligible.
PPC Land notes that healthcare had previously been excluded from ads in AI Overviews, and reads the disclaimer limit as effectively ruling out drugs that need fair-balance language. That is the outlet's inference. The October news suggests the exclusion has loosened, but only for "certain" products.
| Date | Event | Source |
|---|---|---|
| Aug 2025 | Google removed the Restricted Medical Content label, keeping certification | PPC Land |
| 20 May 2026 | Marvin confirms healthcare test at Google Marketing Live | PPC Land |
| 2 Jun 2026 | Test reported: no pinning or disclaimers | Search Engine Land |
| Aug 2026 | Adthena samples 50,000 US AI Mode ad placements | Adthena |
| 12-13 Oct 2026 | Prescription drug ads test reported | Adweek, SER |
Policy background you still have to respect
Nothing in the test replaces Google's standing rules. The Google Ads healthcare and medicines policy says some healthcare content cannot be advertised at all and other content is allowed only in specific countries and only for approved advertisers. Many topics need Google certification, and in some countries third-party approval such as LegitScript or NABP applies to online pharmacies and telemedicine. Offering prescription drugs without a prescription is treated as an egregious violation that can lead to suspension without warning. Read your country's table, because the requirements vary by market and I have not summarised them all here.
What the data says about actual exposure
Adthena analysed 50,000 US AI Mode ad placements collected 2-25 August 2026. It found 491 health-adjacent advertisers and zero placements from a major pharma manufacturer or leading prescription brand. Adthena sells ad-tracking software, so weigh the framing accordingly, and the sample predates the October test.
Adthena also notes that brand-name searches rarely trigger AI Mode ads; condition, treatment and comparison questions do. That matches how people use AI for health, though note the EMARKETER statistics (such as 40% of AI health users researching medications) come from separate surveys with different methods, and should not be stacked together.
Ads in AI answers sit inside a conversation about conditions and treatments, which raises the review bar.
What this changes for different teams
Pharma brand and agency teams
The new surface sits in the medication decision path. Your medical, legal and regulatory review (MLR) process needs a defined answer to: which assets may run, who monitors placements, and who can pause. Align compliance, creative and media now, as Adthena also recommends.
Telehealth, online pharmacy and clinic marketers
If you already hold the relevant Google certification, check whether your PMax, AI Max, Shopping and broad-match campaigns could serve in AI surfaces. Do not assume they do. Document the review date and what you saw.
Organic and content teams
Ads will not stop AI answers citing independent sources. Medical content remains a YMYL area, so primary sourcing, named reviewers and dated updates matter. See my notes on healthcare marketing for AI search and Google's AI Mode ad slots.
India-based marketers
The test is reported as US-only. Indian advertising for medicines is governed by separate rules and the platform's local policies. I did not research those here, so do not read this post as saying anything about India eligibility.
A five-step plan for this week
- Audit campaign types. List PMax, AI Max, Shopping and broad-match campaigns in healthcare accounts and who owns each.
- Check negatives and exclusions. The reports say negative keyword lists still apply; confirm in your account.
- Set up independent monitoring. Because Google Ads gives no AI-placement report, use prompt sampling or a third-party tool and keep screenshots with dates.
- Write the MLR question list. Include disclaimers, fair balance, brand versus unbranded copy and escalation paths.
- Log changes in a notes file. Record each observation with date and source so you can separate reality from rumour.
A short audit-and-monitor loop is more useful than guessing what the test will become.
What I would not do
- Do not move budget on the strength of a test announcement.
- Do not promise a client results from AI Mode placement; nobody has published outcome data for pharma.
- Do not copy EMARKETER or Adthena statistics into decks without labelling the source and date.
- Do not treat "may show" as "will show". Schwartz himself saw no examples.
FAQ
Is Google really showing prescription drug ads in AI Mode?
A Google spokesperson told Adweek it is testing standard text and Shopping ads in AI Mode and AI Overviews, including certain pharmaceutical products, in the US. Search Engine Roundtable's author could not find live examples when he looked on 13 October.
Did Google change its pharma advertising policy?
Google told Search Engine Roundtable there were no recent policy changes. The difference is where eligible ads may appear, not a new written rule, as far as public reporting shows.
Do pharma advertisers need certification?
Existing prescription drug advertising rules apply, and reports say Google's pharmaceutical certification is required. Check Google Ads policy pages for your country, because I could not confirm the exact wording from Google's own documentation.
Can ads with risk disclaimers run in AI Mode?
The June test excluded ads with pinning or text disclaimers. One secondary report says the October phase allows disclaimers in some campaign types; the details are not confirmed, so check with your Google representative.
Is this available in India?
Reporting describes the test as US-only. I found no source confirming an India rollout, so plan on the assumption that it is not available.
Which campaign types are involved?
The June healthcare test named Performance Max, AI Max with search term matching, Shopping and broad match. The October reports mention text and Shopping ads. There is no separate "AI Mode campaign" type.
How can I tell whether my ads appeared in AI Mode?
Google Ads does not currently provide an AI-placement report, according to Adthena. You will need prompt-sampling or third-party tracking, plus dated screenshots.
Will this reduce organic visibility for health content?
There is no published evidence of that yet. Sponsored sections are labelled, and organic citations are chosen separately. Keep your sourcing and review process strong either way.
Should health brands pause organic work to focus on ads?
No. Ads and organic answers serve different roles, and the pharma ad test is limited and uncertain. Keep investing in accurate, reviewed content.
Work with me
I'm Younus Fardeen, an organic growth and AEO marketer with 4+ years of marketing experience in edtech and startups. If you want help working out how AI search changes your content and channel plan, see my work and reach me through the contact form at https://younusfardeen.in.